Viagra

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
16-02-2024
Tabia za bidhaa Tabia za bidhaa (SPC)
16-02-2024

Viambatanisho vya kazi:

sildenafil

Inapatikana kutoka:

Upjohn EESV

ATC kanuni:

G04BE03

INN (Jina la Kimataifa):

sildenafil

Kundi la matibabu:

Urologicals

Eneo la matibabu:

Erectile Dysfunction

Matibabu dalili:

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Viagra to be effective, sexual stimulation is required.

Bidhaa muhtasari:

Revision: 45

Idhini hali ya:

Authorised

Idhini ya tarehe:

1998-09-13

Taarifa za kipeperushi

                                65
B. PACKAGE LEAFLET
66
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
VIAGRA 25 MG FILM-COATED TABLETS
sildenafil
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor, pharmacist or
nurse.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What VIAGRA is and what it is used for
2.
What you need to know before you take VIAGRA
3.
How to take VIAGRA
4.
Possible side effects
5.
How to store VIAGRA
6.
Contents of the pack and other information
1.
WHAT VIAGRA IS AND WHAT IT IS USED FOR
VIAGRA contains the active substance sildenafil which belongs to a
group of medicines called
phosphodiesterase type 5 (PDE5) inhibitors. It works by helping to
relax the blood vessels in your
penis, allowing blood to flow into your penis when you get sexually
excited. VIAGRA will only help
you to get an erection if you are sexually stimulated.
VIAGRA is a treatment for adult men with erectile dysfunction,
sometimes known as impotence. This
is when a man cannot get, or keep a hard, erect penis suitable for
sexual activity.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE VIAGRA
DO NOT TAKE VIAGRA

If you are allergic to sildenafil or any of the other ingredients of
this medicine (listed in section
6).

If you are taking medicines called nitrates, as the combination may
lead to a dangerous fall in
your blood pressure. Tell your doctor if you are taking any of these
medicines which are often
given for relief of angina pectoris (or “chest pain”). If you are
not certain, ask your doctor or
pharmacist.

If you are using any of the medicines known as nitric oxide donors
such as amy
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
VIAGRA 25 mg film-coated tablets
VIAGRA 50 mg film-coated tablets
VIAGRA 100 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains sildenafil citrate equivalent to 25,
50 or 100 mg of sildenafil.
Excipient with known effect
_VIAGRA 25 mg tablets _
Each film-coated tablet contains 0.9 mg lactose (as monohydrate).
_VIAGRA 50 mg tablets _
Each film-coated tablet contains 1.7 mg lactose (as monohydrate).
_VIAGRA 100 mg tablets _
Each film-coated tablet contains 3.5 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
VIAGRA 25 mg tablets
Blue, rounded diamond-shaped film-coated tablets, marked “PFIZER”
on one side and “VGR 25” on
the other.
VIAGRA 50 mg tablets
Blue, rounded, diamond-shaped film-coated tablets, marked “PFIZER”
on one side and “VGR 50” on
the other.
VIAGRA 100 mg tablets
Blue, rounded diamond-shaped film-coated tablets, marked “PFIZER”
on one side and “VGR 100” on
the other.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
VIAGRA is indicated in adult men with erectile dysfunction, which is
the inability to achieve or
maintain a penile erection sufficient for satisfactory sexual
performance.
In order for VIAGRA to be effective, sexual stimulation is required.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Use in adults _
The recommended dose is 50 mg taken as needed approximately one hour
before sexual activity.
Based on efficacy and tolerability, the dose may be increased to 100
mg or decreased to 25 mg. The
maximum recommended dose is 100 mg. The maximum recommended dosing
frequency is once per
day. If VIAGRA is taken with food, the onset of activity may be
delayed compared to the fasted state
(see section 5.2).
Special populations
_ _
_Elderly _
Dose adjustments are not required in elderly patients (≥ 65 years
old).
_Renal impairment _
The dosing recommendations 
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kibulgaria 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kihispania 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kicheki 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kidenmaki 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kijerumani 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kiestonia 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kigiriki 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kifaransa 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kiitaliano 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kilatvia 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kilithuania 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kihungari 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kimalta 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kiholanzi 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kipolandi 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kireno 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kiromania 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kislovakia 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kislovenia 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kifinlandi 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kiswidi 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 12-07-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kinorwe 16-02-2024
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 16-02-2024
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 16-02-2024
Tabia za bidhaa Tabia za bidhaa Kroeshia 16-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 12-07-2016

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati